Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 8 9 10 11 12 … 50 Next »

Ilumya / Ilumetri efficacy using phase 2b/3 trial data.

Threaded Mode
Ilumya / Ilumetri efficacy using phase 2b/3 trial data.
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 59,567
Threads: 3,623
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 3
Psoriatic Arthritis Score: 3
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#1
News  Fri-10-01-2020, 21:25 PM
This study evaluated the effects of patient demographic and disease characteristics on Ilumya / Ilumetri (tildrakizumab) efficacy using phase 2b/3 trial data.

Quote:
Background:
Tildrakizumab is a high‐affinity, anti–interleukin‐23p19 monoclonal antibody approved for treatment of moderate to severe plaque psoriasis.

Objectives:
To evaluate the effects of patient demographic and disease characteristics on tildrakizumab efficacy using phase 2b/3 trial data.

Methods:
Data from patients who received placebo, or tildrakizumab 100 or 200 mg, in P05495 [NCT01225731], reSURFACE 1 [NCT01722331] and reSURFACE 2 [NCT01729754] were analysed. Patient subgroups were defined by age, sex, race, weight, self‐reported psoriatic arthritis, failure of ≥1 traditional systemic treatment, and prior biologic use. Percentage of Psoriasis Area and Severity Index (PASI) 75 and 90 responders at Week 12 were compared across treatment arms in each subgroup. Absolute PASI at Weeks 0 and 12 were also determined for each subgroup.

Results:
Among patients randomised in P05495 (N = 355), reSURFACE 1 (N = 772) and 2 (N = 1090), percentage of PASI 75 and 90 responders were significantly greater for each tildrakizumab dose vs. placebo (P<0.0001). PASI 75 and 90 responder percentages were numerically greater in patients <65 years of age, body weight ≤90 kg, without psoriatic arthritis, and with no prior biologic exposure (only PASI 90), vs. their counterparts in corresponding subgroups. There were no clear or consistent differences in efficacy between the other subgroups. Absolute PASI scores were generally similar across subgroups.

Conclusions:
Small numerical differences in tildrakizumab efficacy were observed between subgroups defined by patient age and weight, presence of psoriatic arthritis, and prior biologic use. These differences were not clinically meaningful; however, analyses of long‐term data may be of value. Tildrakizumab efficacy did not differ with respect to patient sex or race, or number of prior failed conventional systemic treatments. Overall, these results suggest tildrakizumab may be appropriate for treatment of moderate to severe plaque psoriasis in patients with a range of demographic and disease characteristics.


Source: onlinelibrary.wiley.com

*Early view funding unknown.

Ilumetri / Ilumya (tildrakizumab)
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News JNJ-2113 for psoriasis Phase 2b results Fred 4 855 Wed-12-07-2023, 11:52 AM
Last Post: Turnedlight
News Tremfya for psoriatic arthritis phase 3b data Fred 0 544 Wed-31-05-2023, 16:26 PM
Last Post: Fred
News Bimzelx and psoriatic arthritis long term data Fred 0 506 Wed-31-05-2023, 14:00 PM
Last Post: Fred
News Izokibep and psoriatic arthritis 46 week data Fred 0 746 Tue-11-04-2023, 13:35 PM
Last Post: Fred
News Cosentyx efficacy, safety and tolerability in children with psoriasis Fred 0 733 Sat-08-04-2023, 11:57 AM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2023 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode